chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Dysgeusia; Aguesia, Ageusia; Dysgeusia. Information has been received from a registered nurse concerning a 34 year old white male with no allergies or medical conditions who in the a.m. of 26-FEB-2003 was vaccinated IM in the left deltoid with a first dose of hepatitis B virus vaccine rHBsAg (yeast) (lot #644199/0835M). After the first dose of vaccine, the patient noted a "metal" taste and could not taste food as long as the metallic taste was present. It persisted for four to five days. On 26-MAR-2003 at 9:00 a.m. the patient was vaccinated IM in the right deltoid with a second dose of hepatitis B virus vaccine rHBsAg (yeast) (lot # 644099/0835M). There was no illness at the time of vaccination. The reporter indicated that on 26-MAR-2003 at 9:00 p.m., about 12 hours after the vaccine was given, the patient noted a "metal" taste and could not taste food as long as the metallic taste was present. Unspecified medical attention was sought. There was no diagnostic tests or laboratory results available. No further information is expected.
Day of vaccination (Day 1): Feeling of coldness on left side of chest, like there's ice in my chest; brought to ED for observation. EKG  done, WNL. Given tylenol then sent home with benadryl. Once home, felt very, very cold, had to wear long sleeve shirt and fleece pants;  persisted up to the present.  Day 2: additional symptoms: dizziness, slight SOB, headache, head felt heavy, slight cough;  SOB resolved by day 3. Other symptoms still present. Day 3: additional symptoms- salty taste in mouth & numbness of cheeks. Day 4: Dizziness, headache, salty taste, numbness of cheeks worsened. Went to ED, given IV fluids, sent home. Day 5 - diarrhea; Day 6 - diarrhea resolved; headache, dizziness/lightheadedness persisted.  + nausea/retching but no vomiting v
Headache; This case was reported by a consumer via call center representative and described the occurrence of headache in a female patient who received HAV (Havrix 720 adult) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   The patient's past medical history included meniere's disease. Previously administered products included Flu vaccine (20 plus years ago) and Pneumonia vaccine (20 plus years ago).   On an unknown date, the patient received the 1st dose of Havrix 720 adult and Havrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Havrix 720 adult and Havrix Pre-Filled Syringe Device, the patient experienced headache. On an unknown date, the outcome of the headache was recovered/resolved.   It was unknown if the reporter considered the headache to be related to Havrix 720 adult and Havrix Pre-Filled Syringe Device.This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt date: 03-Jan-2023. Reporter's Comment: The reporter was the patient. The reporter also stated that 20 plus years ago she had the flu vaccine (unknown name and manufacturer) and the pneumonia vaccine (unknown name and manufacturer) and was diagnosed with Meniere's disease. Patient refused to give consent or provide demographic details.   All elements of the flu and pneumonia vaccine are unknown due to time period that has elapsed. The reporter did not consent to follow-up.
Hives to right side of face and chest. No respiratory distress. Hives lessened with use of BENADRYL.
This spontaneous report was received from a 64 year old patient referring to herself. The patient's concurrent conditions and medical history were not reported. On 27-OCT-2014, the patient was vaccinated with ZOSTAVAX (strength, dose, route of administration and lot number not reported). On the same date, the patient also received unspecified Flu shot. Concomitant medications were not reported. On an unknown date in early November 2014, the patient experienced itching and scratching and went to the physician. The patient reported that on an unknown date in November 2014, before Thanksgiving, she experienced horrible abdominal pain and was admitted into the hospital for a week. Several tests were run and all tests results were negative. The patient continued to have same abdominal symptoms after Christmas and was readmitted into the hospital for another week. On an unknown date, additional tests were run and all tests results were negative. The patient was still having abdominal pain and was again readmitted to the hospital on an unknown date in mid-January 2015 for a week. The patient was given two colonoscopies and the tests found several ulcers. On unspecified date blood test was done, results was not reported. All medication prescribed during the patient's hospitalization are unspecified. At the present time, the ulcers were gone. Patient also had unspecified skin problems due to which she couldn't wear clothes and nothing could touch her skin. The patient had to buy extra-large clothes. The patient's present status was reported as recovering. The causality assessment was not provided. Additional information has been requested.
12-14-05 DTAP immunizations given - infant Tylenol given right after and at approx 3 pm that day. Next day 12/15 3pm Temp 102.6, infant flushed and warm, sleeping more than normal. Mother took child to ER - Motrin given temp down to normal. By discharge child examined no elevation after that. Discharge  same day.
Site of injection is itching; Site of injection has red mark (3 inches); This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Site of injection is itching) and VACCINATION SITE ERYTHEMA (Site of injection has red mark (3 inches)) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (Site of injection is itching) and VACCINATION SITE ERYTHEMA (Site of injection has red mark (3 inches)). At the time of the report, VACCINATION SITE PRURITUS (Site of injection is itching) and VACCINATION SITE ERYTHEMA (Site of injection has red mark (3 inches)) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported by investigator o No treatment medications provided by the reporter.
When patient was seen in our office on 4-16-2011, the parent stated child had uncontrollable crying and a red & swollen (L) leg following vaccine on 2-16-11.
pt recv 2 doses of vax 15MAY96 & 13JUN96 & 21AUG96 a blood test revealed a negative titer;
Presented w c/o fever & SOB; COVID-19+; tx w/steroids, Vit C, zinc
Left thigh with redness and swelling, warm to touch and pt complains of pain and discomfort.
The pt developed fever then followed by chickenpox rash from waist up. Parent took the pt to a physician and was instructed to give Benadryl and Tylenol if needed.
This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm AFTER FIRST DOSE) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030M20A and 047A21A) for COVID-19 vaccination. The patient's past medical history included Accident automobile (had an injury from a car accident and normally gets numbing and tingly in the arm.). On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Feb-2021, the patient experienced PAIN IN EXTREMITY (Sore arm AFTER FIRST DOSE). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A) at an unspecified dose and frequency and LORATADINE (CLARITINE) at an unspecified dose and frequency. On 12-Feb-2021, PAIN IN EXTREMITY (Sore arm AFTER FIRST DOSE) had resolved. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. Concomitant product use was not provided by the reporter. Treatment information was not provided. Lab details were not provided.
no appetite; chills; cough; fatigue; shortness of breath; This is a spontaneous report from a contactable consumer (patient). A 50-year-old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiry date unknown), via an unspecified route of administration on 02Jan2021 at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced chills, cough, fatigue, shortness of breath, no appetite on 02Jan2021. The events resulted in: Doctor or other healthcare professional office/clinic visit. Event treatment included antibody IgG. Covid was tested post vaccination in Jan2021 with unknown result. The outcome of the events was recovering.   Information on Lot/batch number has been requested.
PT states her arm bruised up a week after the vaccination.  She states the area is yellow in color.  She denies pain, fever or any other reaction associated with the vaccine.  She states it has not changed since it developed 2 days ago.  She states she feels fine, but would like the reaction reported.
Have it now, Had vaccinated doubled shots; Have it now, Had vaccinated doubled shots; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.     Additional Information: GSK Receipt Date: 30-Aug-2022 Reporter's Comments: The reporter reported the case via interactive digital media. The patient stated that he/she had it now (at the time of reporting), just would not go away. The patient had vaccinated doubled shots Additional Supportive Information: This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule and laboratory confirmation were unknown at the time of reporting. The follow-up would not possible as no contact details were available.
Narrative:  Patient had severe nausea and vomiting along with fevers and was seen in the emergency room due to the severity of symptoms.
6/7 - 6/30/22 pt was hospitalized for increasing confusion and hallucinations; CT head and CXR showed no acute disease; admitted for possible UTI; tx with IVFs and ABX; left popliteal vein DVT; anticoagulation; pt dc'd to SNF on 6/30/22 and was found to be positive for COVID on admission; asymptomatic; pt's condition did not improve and he passed away in the SNF
On Friday 05/06/22, I noticed a scratchy throat. Woke up the next morning and was very stuffy and thought I was getting a cold. So I did a rapid test and surprisingly tested positive. I sent the results to my doctor who then prescribed Paxlovid, but I wasn't able to begin until Monday 5/9. due to a shortage. On Sunday, I was still feeling bad with an awful sore throat and stuffiness, it felt like a really bad cold. But after beginning the Paxlovid, I then began to feel better and have been getting better since. With the exception of the extreme metallic taste, I've been experiencing since beginning Paxlovid.
First 2 days fever, chills, headache, aching. Then soa, headache, diarrhea, nausea vomiting still going on as of  07/03/2021
sleepy; just don't feel good; arm hurts more than suggested.; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (sleepy), FEELING ABNORMAL (just don't feel good) and PAIN IN EXTREMITY (arm hurts more than suggested.) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination.     no medical history was provided by reporter.  Concomitant products included AMOXYCILLIN [AMOXICILLIN] for an unknown indication.    On 13-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-May-2021, the patient experienced SOMNOLENCE (sleepy), FEELING ABNORMAL (just don't feel good) and PAIN IN EXTREMITY (arm hurts more than suggested.). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form. At the time of the report, SOMNOLENCE (sleepy), FEELING ABNORMAL (just don't feel good) and PAIN IN EXTREMITY (arm hurts more than suggested.) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Initial case retrieved from the scientific literature in a Foreign country on 27 December 2010. The article identifies 16 patients who experienced adverse events following H1N1 vaccination or infection; 3 of the 16 received either PANENZA or H1N1 vaccine (manufacturer unknown), 11 received H1N1 vaccines produced by other manufacturers, and 2 were not vaccinated. This case contains information for 1 of the 3 patients who received PANENZA or H1N1 (manufacturer unknown); information for the other 2 patients is contained in cases E2010-05049 and 2011-00025. The article states that 2 of the 4 post-vaccination cases identified at a University were vaccinated in a foreign country. A summary table presented in the article indicates that 2 of the 4 patients received PANDEMRIX, 1 patient received PANENZA, and 1 patient received an H1N1 vaccine (no adjuvant from an unknown manufacturer). A 9-year-old patient received an injection of PANDEMIC (manufacturer and lot number not reported) in December 2009. In January 2010, also reported as 2 weeks post-vaccination, the patient began experiencing symptoms of excessive daytime sleepiness and developed cataplexy. The patient underwent extensive testing, including serum, cerebrospinal fluid, and DNA testing for biochemical measurements. Results included a positive HLA DQB1 0602, with severe sleepiness and definite/severe cataplexy. Anti-TRIB2 was negative. No additional information was reported for this patient. Documents held by sender: None.
On May 15, 1999 the pt experienced vesicula macula papular rash, in clusters and singles on her back, neck, ear, both legs. She also experienced a water blister that sometimes feels like knots on her upper arm incision. The patient was seen by MD on May 17, 1999, who upon physical examination diagnosed her with chickenpox. Treatment was acyclovir. It was reported the pt chickenpox persisted.
Aching, redness and swelling at the injection site; Redness and swelling at the injection site; Swelling at the injection site; dizziness; Pain upon movement of her left arm/; shivers; fatigue; not feeling well; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30th July 2020, the patient received the 2nd dose of Shingrix. On 30th July 2020, less than a day after receiving Shingrix, the patient experienced feeling unwell. On 31st July 2020, the patient experienced injection site pain, injection site erythema, injection site swelling, dizziness, pain upon movement, shivers and fatigue. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site swelling, dizziness, pain upon movement, feeling unwell, shivers and fatigue were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema, injection site swelling, dizziness, pain upon movement, feeling unwell, shivers and fatigue to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in her left arm yesterday at her cardiologist office and started not feeling well. The patient was feeling worse, has aching, redness and swelling at the injection site.  The patient was also experiencing shivers, fatigue and pain upon movement of her left arm. The reporter consented to follow up.
Patient in to clinic for 2nd shingrex. Patient stated that he had become deathly ill for several days after 1st injection. Patient stated that lymph nodes in right axillary and arm had been swollen, & deathly ill...lymph nodes in R axillary and arm swollen
This spontaneous report as received from a 25 year old non-pregnant female patient, refers to herself. The patient's concurrent conditions included endometriosis, hamstring weakness, post-traumatic stress disorder (PTSD) and allergy to penicillin and KEFLEX. On 01-APR-2015, the patient received either GARDASIL or GARDASIL 9 first dose, dose, route, lot# and expiration date were not reported. Concomitant therapies included DEPO-PROVERA. The patient reported, that six hours after vaccination, on 01-APR-2015, she experienced a drugged/high feeling, excessive laughing, dizziness, hot flashes, nausea, fatigue, loss of appetite, weakness and shaking in her legs, rash, itching, fogginess and inability to think clearly. The patient sought medical attention. On 02-APR-2015, she returned back to the physician's office and was provided BENADRYL as a treatment and she was informed to discontinue the subsequent doses of GARDASIL/GARDASIL 9 and the therapy was not reintroduced. On 03-APR-2015, the patient was seen in the emergency room (ER) and admitted in the hospital, she underwent a magnetic resonance imaging (MRI) of brain, neck and spine and electroencephalography (EEG). The patient also received an intravenous dose of steroids, PEPCID and VISTARIL as treatments, while hospitalized. The patient was hospitalized for 4 days (from 03-APR-2015 to 07-APR-2015). At the time of reporting, the patient was recovering from the events. The relatedness between the events and GARDASIL/GARDASIL 9 was not provided. Upon internal review, hot flashes, rash and itching were considered to be medically significant, as they were treated with IV steroids. Additional information has been requested.
Sore arm; Muscle cramping; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) and MUSCLE SPASMS (Muscle cramping) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045B21A) for COVID-19 vaccination.     Concurrent medical conditions included Depression (The patient's pre-existing medical condition include anti-depressant.).    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm) and MUSCLE SPASMS (Muscle cramping). At the time of the report, PAIN IN EXTREMITY (Sore arm) and MUSCLE SPASMS (Muscle cramping) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Patient received only a tiny amount of the vaccine / the liquid was all down her arm /lower volume administered; The device failed and most of the shot sprayed outside the needle; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient received only a tiny amount of the vaccine / the liquid was all down her arm /lower volume administered) and DEVICE CONNECTION ISSUE (The device failed and most of the shot sprayed outside the needle) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 068H21A, 013M20A and 007D21A) for COVID-19 vaccination. No Medical History information was reported.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Jan-2022, the patient experienced ACCIDENTAL UNDERDOSE (Patient received only a tiny amount of the vaccine / the liquid was all down her arm /lower volume administered) and DEVICE CONNECTION ISSUE (The device failed and most of the shot sprayed outside the needle). On 21-Jan-2022, ACCIDENTAL UNDERDOSE (Patient received only a tiny amount of the vaccine / the liquid was all down her arm /lower volume administered) and DEVICE CONNECTION ISSUE (The device failed and most of the shot sprayed outside the needle) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient was not on any concomitant medication. Treatment information was not provided. The dose could not be completely administered to the patient. The patient did not experience any symptoms after receiving the vaccine.
Information has been received from a medical assistant concerning a 13 year old female who was vaccinated with three doses of GARDASIL (lot # not reported). Subsequently the patient developed a rash on her hand after receiving her first and second dose of GARDASIL. The patient also developed a rash on third dose. On the third dose, the rash spread from her hand to her thighs. Unspecified medical attention was sought. No further information is available.
Morning of 12/16 family found him unresponsive in bed and noted emesis in bed. Parents started CPR. Paramedics arrived and in full arrest. Resuscitation attempted in ER for 1 hour. No cardiac activity, and resuscitation attempts stopped.
Patient received both PCV20 and Tdap around 11:20 at the same time during routine clinic visit. Approximately 1hr later, prt reported difficulty breathing and malaise. She was noted to have blotchy erythema to her face but no respiratory distress upon assessment by MD. Symptoms resolved with cold packs and ice water.
This spontaneous case, initially received from other health professional (nurse) on 10-Oct-2018, concerns a male patient of an unspecified age. The patient's historical drug included flu vaccine for an unknown indication and developed symptoms of vertigo after vaccination. On an unspecified date, the patient was administered Influenza vaccine (dose, route of administration, anatomical location, batch number, manufacturer, trade name and expiry date: not reported). On an unspecified date, after vaccination, the patient developed symptoms of vertigo. At the time of this report, the outcome of the event was not reported. Non-significant follow up report received on 19-Nov-2018: No new information received. hence, no changes were made in narrative.
no additional AE; VARIVAX was improperly stored and administered; This spontaneous report was received from a medical assistant and refers to a 1-year-old old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 03-DEC-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) 0.5 milliliter, lot # T002843, expiry date 23-JAN-2022 for prophylaxis (strength and route of administration were not reported). There was no adverse event reported. Administered dose of vaccine experienced the temperature excursion of 31.6 degrees Fahrenheit for 22 days. Data logger was not involved. There were no previous excursions reported.
Pt recvd vax on 19JUN92; mom describes @ f/u visit, pt had 4 hrs of unconsolable crying that was also unusual cry; unrelieved sx w/APAP or holding;